222 related articles for article (PubMed ID: 29967251)
1. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
Baro M; Lopez Sambrooks C; Quijano A; Saltzman WM; Contessa J
Clin Cancer Res; 2019 Jan; 25(2):784-795. PubMed ID: 29967251
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy.
Contessa JN; Bhojani MS; Freeze HH; Ross BD; Rehemtulla A; Lawrence TS
Clin Cancer Res; 2010 Jun; 16(12):3205-14. PubMed ID: 20413434
[TBL] [Abstract][Full Text] [Related]
3. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.
Lopez Sambrooks C; Baro M; Quijano A; Narayan A; Cui W; Greninger P; Egan R; Patel A; Benes CH; Saltzman WM; Contessa JN
Cancer Res; 2018 Sep; 78(17):5094-5106. PubMed ID: 30026325
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells.
Contessa JN; Bhojani MS; Freeze HH; Rehemtulla A; Lawrence TS
Cancer Res; 2008 May; 68(10):3803-9. PubMed ID: 18483264
[TBL] [Abstract][Full Text] [Related]
5. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.
Lopez-Sambrooks C; Shrimal S; Khodier C; Flaherty DP; Rinis N; Charest JC; Gao N; Zhao P; Wells L; Lewis TA; Lehrman MA; Gilmore R; Golden JE; Contessa JN
Nat Chem Biol; 2016 Dec; 12(12):1023-1030. PubMed ID: 27694802
[TBL] [Abstract][Full Text] [Related]
6. Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity.
Cazet A; Charest J; Bennett DC; Sambrooks CL; Contessa JN
PLoS One; 2014; 9(10):e110345. PubMed ID: 25314669
[TBL] [Abstract][Full Text] [Related]
7. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.
Carapancea M; Cosaceanu D; Budiu R; Kwiecinska A; Tataranu L; Ciubotaru V; Alexandru O; Banita M; Pisoschi C; Bäcklund ML; Lewensohn R; Dricu A
J Neurooncol; 2007 Dec; 85(3):245-54. PubMed ID: 17568996
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
13. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.
Contessa JN; Abell A; Valerie K; Lin PS; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):851-8. PubMed ID: 16751066
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Kriegs M; Gurtner K; Can Y; Brammer I; Rieckmann T; Oertel R; Wysocki M; Dorniok F; Gal A; Grob TJ; Laban S; Kasten-Pisula U; Petersen C; Baumann M; Krause M; Dikomey E
Radiother Oncol; 2015 Apr; 115(1):120-7. PubMed ID: 25796091
[TBL] [Abstract][Full Text] [Related]
15. Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.
Vehlow A; Klapproth E; Storch K; Dickreuter E; Seifert M; Dietrich A; Bütof R; Temme A; Cordes N
Oncotarget; 2017 Jul; 8(30):49224-49237. PubMed ID: 28514757
[TBL] [Abstract][Full Text] [Related]
16. Targeting STT3A-oligosaccharyltransferase with NGI-1 causes herpes simplex virus 1 dysfunction.
Lu H; Cherepanova NA; Gilmore R; Contessa JN; Lehrman MA
FASEB J; 2019 Jun; 33(6):6801-6812. PubMed ID: 30811219
[TBL] [Abstract][Full Text] [Related]
17. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study.
Colen CB; Seraji-Bozorgzad N; Marples B; Galloway MP; Sloan AE; Mathupala SP
Neurosurgery; 2006 Dec; 59(6):1313-23; discussion 1323-4. PubMed ID: 17277695
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
Bhattacharya P; Shetake NG; Pandey BN; Kumar A
Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo.
Nyati MK; Maheshwari D; Hanasoge S; Sreekumar A; Rynkiewicz SD; Chinnaiyan AM; Leopold WR; Ethier SP; Lawrence TS
Clin Cancer Res; 2004 Jan; 10(2):691-700. PubMed ID: 14760092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
